ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0885

Impact of the Ratio of Monocyte to High-Density Lipoprotein Cholesterol on Cardiovascular Outcome in Incident Dialysis Patients

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Jeong, Min Gyo, Catholic University of Korea, Incheon, Korea (the Republic of)
  • Yoon, Hye Eun, Catholic University of Korea, Incheon, Korea (the Republic of)
  • Shin, Seok Joon, Catholic University of Korea, Incheon, Korea (the Republic of)
  • Lee, Yeonhee, Catholic University of Korea, Incheon, Korea (the Republic of)
  • Kim, Da won, Catholic University of Korea, Incheon, Korea (the Republic of)
Background

Monocyte count to high-density lipoprotein ratio (MHR) is a well known risk factor of cardiovascular (CV) complications as an indicator of inflammation and atherosclerosis. We evaluated the impact of the MHR value on the CV outcomes in end-stage kidney disease (ESKD) patients. The primary outcome was comparison of cardiovascular event-free survival rate between the low MHR group and the high MHR group. The secondary outcome included all-cause mortality, overall CV mortality and possibility of MHR as an independent risk factor for CV complication.

Methods

The medical records of 719 ESKD patients who started maintenance dialysis between January 2006 and July 2017 were reviewed. Patients were divided into low MHR and high MHR groups based on the median MHR value.

Results

Overall CV event was 130 cases, 55 in the low MHR group and 75 in the high MHR group, respectively. The CV event-free survival rate was significantly lower in the high MHR group compared to the low MHR group (47.6% vs. 57.5%, P = 0.017). Of the 577 enrolled patients, there was no statistical difference in all-cause mortality between the two groups during a mean follow-up of 3.2 years (P = 0.371). Overall CV mortality rate was also comparable between the two groups (P= 0.615). In multivariate Cox regression analysis, high MHR was an independent predictor for CV events (HR 1.463, 95% CI, 1.019 – 2.102; P = 0.039) even after adjustment for age, smoking, diabetes, body mass index, C-reactive protein, and previous CV disease.

Conclusion

In conclusion, high MHR at the time of dialysis initiation in the incident ESKD patients may be a simple and useful method for predicting development of CV complication.